Founder and Managing Director of Angine as well as the Founding Partner of China "Pharma and MedTech BD Alliance" & Innovation Center. Leo has 25 years of experiences of the international business development in the pharmaceutical industry, and as the project leader he once managed more than 10 global transaction deals with the models of IP license-in, JV, distribution rights granting as well as overseas investment. Before founding Angine, Leo once was the Global Head and Director of International Business Development oftwo Pharmaceutical public companies in China. Besides the position in Angine,Leo also serves as Executive Director of Internationalization Working Committee of China Pharmaceutical Enterprise Association (CPEA). Leo graduated from Peking Universityand obtained the Master Degree (M.E) of Pharmaceutical Engineering.

Partner for Global Supply Chain & Compliance. Howard was gratuated from Peking University with the master degree of Pharma Engineering. He has more thant 30 Years of pharma supply chain and production management experiences. Once served as head of tech transfer and CMC in two MNC China sites (Janssen, Sanofi ) for more than 20 years. Has rich practical experience in tech. transfer, supply chain mangement cGMP compliance and and Operation Efficiency.

Partner and Senior Consultant. 25 years of experience in pharmaceutical quality management of drug substances, solid dose and sterile injectionproductsfor the establishment, maintenance and continuous improvement of quality systems and quality risk management systems. Familiar with international regulations (e.g. FDA, ICH, WHO, PIC/S, PMDAGMP, etc.) and accredited as a member of API FDA Accreditation and WHO PQfor the preparation of accreditation and participation in on-site inspections and productregistrationfor various overseas markets. Ten years' work experience in Sanofi China, including quality assurance (QA), quality compliance, projectmanagement and quality risk management.

Partner for R&D and BD. Dr. Liang obtained his PhD in molecular biology and pharmacology from Purdue University, and was a postdoctoral fellow and researcher at the National Institutes of Health (NIH). He has more than 30 years of experiences in biomedical research and drug development, as well as BD, in China and the United States. He had worked for a leading CRO company in China for 10 years and led a team to provide drug research and development services for global pharmaceutical companies such as drug screening, in vitro and in vivo pharmacological researches, and disease mechanism researches. Dr. Liang had worked in a US pharmaceutical company for the development of rare disease drugs.

Company Expert Committee Head.With more than 40years academic and business management experiences in the pharmaceutical industry, Mr. Xielong Luo is a veteran of drug research & development, pharma international collaboration, China market access policy as well as new business funding and investment. Mr. Luo once was the Executive Director of Global Health Forum (GHF) of Boao Forum of Asia (BAF), a international exchanges platform for China and overseas in term of the health care and health economy. He is also the Director of Internationalization Working Committee of China Pharmaceutical Enterprise Association (CPEA),Director of Internationalization WorkingCommittee China OTC Association andDirector of Zhejiang Yangtze Delta Region Biomedical Research and Development Center. Mr. Luo was educated in China and US with the clinical medicine background.